Q32 Bio Inc. Executive Compensation Details Revealed
Ticker: QTTB · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1661998
| Field | Detail |
|---|---|
| Company | Q32 Bio Inc. (QTTB) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
Q32 Bio exec comp details out for 2023-2024, focus on equity awards & fair value changes.
AI Summary
Q32 Bio Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation for the fiscal years ending December 31, 2023, and December 31, 2024. The filing includes information on equity awards granted, their fair value as of the end of the respective years, and changes in fair value for outstanding and unvested awards. Key individuals mentioned in relation to these awards include Paul Alloway, Jodie Morrison, and Albert Seymour.
Why It Matters
This filing provides transparency into how Q32 Bio Inc. compensates its top executives, offering insights into the company's valuation of its equity awards and its incentive structures.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can indicate potential shifts in management's financial incentives and the company's valuation of its stock, which could impact investor sentiment.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period for executive compensation)
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation)
Key Players & Entities
- Q32 Bio Inc. (company) — Filer of the DEF 14A
- Paul Alloway (person) — Executive compensation details
- Jodie Morrison (person) — Executive compensation details
- Albert Seymour (person) — Executive compensation details
- Homology Medicines, Inc. (company) — Former company name
FAQ
What is the primary purpose of this DEF 14A filing for Q32 Bio Inc.?
The primary purpose is to disclose information regarding the compensation of the company's named executive officers for the fiscal years ending December 31, 2023, and December 31, 2024.
Who are some of the key individuals whose compensation is detailed in this filing?
Key individuals mentioned in relation to compensation details include Paul Alloway, Jodie Morrison, and Albert Seymour.
What specific types of compensation are detailed for the executives?
The filing details information related to equity awards, including changes in fair value of outstanding and unvested awards, and fair value as of the end of the fiscal years.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 29, 2025.
What was Q32 Bio Inc.'s former company name?
Q32 Bio Inc.'s former company name was Homology Medicines, Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Paul Alloway regarding Q32 Bio Inc. (QTTB).